Table 1.

FXR1 expression is associated with poor outcomes in multiple human cancers

Cancer type	Outcome	Sample size	HR*	P	Biomarker	Platform
NSCLC stage I	Overall survival	161	1.31	0.018	Protein	IHC
Lung SCC stage I	Overall survival	78	1.44	0.032	Protein	IHC
Lung ADC stage I†	Overall survival	697	1.82	0.007	mRNA	Microarray and RNA-seq
Breast cancer (TCGA)	Overall survival	483	2.75	0.03	mRNA	RNA-seq
Breast cancer (METABRIC)	Disease-specific free survival	1,992	1.43	0.03	mRNA	Microarray
Ovarian cancer (stage I+II)‡	Relapse-free survival	81	5.38	0.001	mRNA	Microarray
Head and neck SCC (TCGA)	Overall survival	300	1.54	0.04	mRNA	RNA-seq
Head and neck SCC§	Metastasis-free survival	81	2.25	0.01	mRNA	Microarray
Total		3,795

^*Hazard ratio (HR) was calculated using multivariate Cox proportional-hazards analysis.

^†HR was derived from a meta-analysis of six independent lung ADC cohorts (SI Appendix, Table S9).

^‡HR was derived from a combined two independent cohorts (GSE9881 and TCGA).

^§HR was derived from E-TABM-302 cohort.